Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
48 Leser
Artikel bewerten:
(0)

Global Regulatory and Pharmaceutical Industry Leaders to Appear as Plenary Speakers at Joint FDA-ISPE CGMP Conference

TAMPA, Fla., April 11, 2012 /PRNewswire-USNewswire/ -- ISPE announced today that it has brought together a substantial line-up of global regulatory officials and pharmaceutical industry leaders to be plenary speakers at the FDA/ISPE co-sponsored "Redefining the 'C' in 'CGMP'" Conference in Baltimore, Maryland, USA on 4 - 5 June 2012. These key regulatory and industry professionals will speak on the key CGMP issues affecting the pharmaceutical industry today.

(Logo: http://photos.prnewswire.com/prnh/20120208/DC49497LOGO)

"This collaborative FDA-ISPE event is on-track to become a landmark conference with unprecedented opportunities for regulators and industry professionals to engage in dialog, solve problems and learn from one another," said ISPE's President and CEO Nancy Berg. "It's not often that a single conference is able to present this many relevant, high-level speakers. The caliber of these speakers illustrates ISPE's and FDA's shared commitment to addressing quality and manufacturing challenges to ensure the safety and availability of the world's drug supply."

Attendees will receive a rare opportunity to hear directly from the policy makers and influencers affecting business and manufacturing in the 21st century. The plenary sessions will consist of premier presentations focused on global quality, worldwide compliance and the future vision of the pharmaceutical industry.

Plenary speakers at this conference include:

  • Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER), FDA, USA
  • Andy Skibo, Executive Vice President, Operations, MedImmune, USA
  • Deborah Autor, Deputy Commissioner for Global Regulatory Operations and Policy, FDA
  • Ilisa Bernstein, Acting Director, Office of Compliance, CDER, FDA
  • Mary Oates, Vice President of GlobalQuality Operations, Pfizer, USA
  • Gerald Heddell, Director of Inspection, Enforcement and Standards, MHRA

More information on the Redefining the "C" in "CGMP" Conference, including complete speaker bios, education details and registration information is available at www.ISPE.org/2012CGMPCompliance.

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is a not-for-profit Society of 22,000 pharmaceutical professionals in 90 countries who use expert knowledge to create high-quality, cost-effective GMP solutions. Founded in 1980, ISPE offers online learning opportunities for a global audience and has its worldwide headquarters in Tampa, Florida, USA; its European office in Brussels, Belgium; an Asia Pacific office in Singapore; and its newest office in Shanghai, China. Visit www.ISPE.org for additional Society news and information.

For more information contact:
Danielle Hould
ISPE Communications Manager
Tel: +1-813-960-2105, ext. 277
email: dhould@ispe.org
www.ISPE.org

SOURCE ISPE

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.